# Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

> **NCT06120140** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 305 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Amivantamab IV
- **DRUG:** Amivantamab SC
- **DRUG:** Lazertinib
- **DRUG:** Doxycycline
- **DRUG:** Minocycline
- **DRUG:** Clindamycin
- **DRUG:** Chlorhexidine
- **OTHER:** Noncomedogenic skin moisturizer
- **OTHER:** Ruxolitinib
- **OTHER:** Tacrolimus
- **DRUG:** Zinc gluconate
- **DRUG:** Propranolol
- **DRUG:** Timolol
- **DRUG:** Clobetasol

## Key facts

- **NCT ID:** NCT06120140
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-16
- **Primary completion:** 2027-05-31
- **Final completion:** 2032-01-31
- **Target enrollment:** 305 (ACTUAL)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06120140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06120140, "Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06120140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*